If any industry had an excuse to sit out the AI wave, it would be pharmaceuticals. Heavy regulation, sensitive data, audit trails on everything. Yet regulated businesses are adopting AI successfully, and how they do it holds lessons for every company worried about the risks.
Our consultants have led AI rollouts inside UK pharma, including Microsoft Copilot adoption and the introduction of AI development tools across the business. Here is what actually works.
Start with the data, not the AI
The instinct is to buy licences and switch AI on. The right first move is the opposite: understand what data the AI will be able to see. An AI assistant connected to your document stores will surface whatever it can access, including the badly permissioned HR folder nobody realised was open to the whole company.
Before any rollout, audit access controls, fix over-permissioned content and decide explicitly what is in scope. In regulated settings this is non-negotiable. Everywhere else it should be.
Govern by default, not by exception
The businesses that get into trouble with AI are the ones where staff adopt tools informally with no rules. Research on UK adoption consistently finds a large gap between how many organisations use AI and how many have any policy governing it, with fewer than one in ten pursuing adoption with defined governance.
The fix does not need to be bureaucratic. A short, clear policy covering what data can go into which tools, which tools are approved, and who to ask when unsure will prevent most incidents. Pair it with approved alternatives so staff are never choosing between breaking the rules and getting their work done.
Pick use cases where safety is built in
Not all AI applications carry the same risk. Drafting internal documents, summarising meetings and answering questions from an approved knowledge base with citations are low-risk, high-value starting points. Anything customer-facing or touching regulated decisions comes later, once governance has matured.
In our pharma work, one of the earliest wins was an internal regulatory knowledge base built on retrieval augmented generation: staff get answers drawn only from vetted, approved documents, with citations. The design itself is the safety control.
Train people properly
The tools are the cheap part. UK research shows a striking pattern: almost every organisation reports an AI skills gap, and roughly two thirds of employees have had no formal AI training. Untrained staff either avoid the tools entirely, wasting the investment, or use them carelessly, creating the risks the governance was meant to prevent.
Effective training is practical and role-specific: real tasks from the person’s actual job, done live with the tool, with the boundaries explained in context. An hour of that beats a day of generic slides.
Prove value early and publicly
Adoption spreads when people see colleagues saving real time. Pick early use cases with visible results: a report that used to take a day now taking an hour, directors self-serving answers that previously queued behind an analyst. Publicise the wins internally. Momentum does more for adoption than any mandate.
The regulated-industry standard is the right standard
Everything above was learned where the cost of getting it wrong is highest. But none of it is pharma-specific. Data governance, clear policy, safe use cases, proper training: that is simply what competent AI adoption looks like in any business.
If you are planning an AI rollout and want it done safely without strangling it in process, book a free AI audit. We will map your starting point and give you a practical adoption plan drawn from experience in the most demanding settings.